Related references
Note: Only part of the references are listed.Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
The high price of anticancer drugs: origins, implications, barriers, solutions
Vinay Prasad et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
S. Vincent Rajkumar et al.
BLOOD (2016)
Multiple myeloma-translation of trial results into reality
Philippe Moreau et al.
LANCET (2016)
New investigational drugs with single-agent activity in multiple myeloma
A. M. Rajan et al.
BLOOD CANCER JOURNAL (2016)
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
Jesus F. San-Miguel et al.
LANCET HAEMATOLOGY (2016)
Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis
Scott Ramsey et al.
HEALTH AFFAIRS (2013)
The High Cost of Cancer Drugs and What We Can Do About It
Mustaqeem Siddiqui et al.
MAYO CLINIC PROCEEDINGS (2012)
Share Paper
